Loading...
BNR logo

Burning Rock Biotech LimitedNasdaqGM:BNR Stock Report

Market Cap US$176.1m
Share Price
US$16.70
My Fair Value
n/a
1Y438.7%
7D-0.4%
Portfolio Value
​
View

Burning Rock Biotech Limited

NasdaqGM:BNR Stock Report

Market Cap: US$176.1m

Burning Rock Biotech (BNR) Stock Overview

Develops and sells cancer therapy selection tests in the People's Republic of China and the United States. More details

BNR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings have grown 21% per year over the past 5 years

Risk Analysis

Volatile share price over the past 3 months compared to the US market


BNR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Burning Rock Biotech Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Burning Rock Biotech
Historical stock prices
Current Share PriceUS$16.70
52 Week HighUS$41.72
52 Week LowUS$2.49
Beta1.5
1 Month Change-22.54%
3 Month Change-44.18%
1 Year Change438.71%
3 Year Change-42.01%
5 Year Change-94.43%
Change since IPO-93.22%

Recent News & Updates

Recent updates

Analysis Article • Jun 21

Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 1x Burning Rock Biotech Limited ( NASDAQ:BNR ) is...
Analysis Article • Mar 25

Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 01

There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

With a price-to-sales (or "P/S") ratio of 1.2x Burning Rock Biotech Limited ( NASDAQ:BNR ) may be sending very bullish...
Analysis Article • Jul 12

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Burning Rock Biotech is US$3.02 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Apr 28

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 23

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 20

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 31

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Burning Rock Biotech press release (NASDAQ:BNR): Q2 GAAP EPS of -$0.37 misses by $0.01. Revenue of $19.5M (-1.0% Y/Y) misses by $2.94M. "Second quarter business volumes have been significantly impacted by Covid related restrictions, with severe volume drops in Shanghai and Beijing; however, pharma service revenues, new products and the in-hospital business outside of Shanghai and Beijing have shown strong growth momentum. Burning Rock therefore retains its full year 2022 revenue guidance of approximately RMB620M for now, and would like to highlight the risks of further Covid related impact in the second half of 2022 which is beyond the Company's control and inherently difficult to forecast."
Seeking Alpha • Jun 06

Burning Rock Localizes As Investors Grow Impatient

The company provides cancer-testing services and related services through its own centrally run labs and increasingly through labs it is setting up within partner hospitals. It’s not often that you hear company officials use the word “horrific” when talking about their business and the overall business climate. Burning Rock’s overall revenue grew 27% in the first quarter year-on-year to 135.5 million yuan.
Analysis Article • Mar 24

We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Nov 17

Following Rough Year, Is Burning Rock Set To Turn The Corner?

Burning Rock expects fourth-quarter revenue to grow just 6% year-on-year due to latest Covid-related travel restrictions in China. Cancer testing specialist’s newer in-hospital lab business could boost growth through its strong scalability potential and lower vulnerability to Covid travel restrictions. Cancer testing specialist expects sharply slower growth this year than previous guidance due to Covid-related travel restrictions.
Analysis Article • Aug 27

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jul 23

A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Burning Rock Biotech...
Analysis Article • May 13

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

BNRUS BiotechsUS Market
7D-0.4%-3.0%-0.3%
1Y438.7%32.9%26.7%

Return vs Industry: BNR exceeded the US Biotechs industry which returned 28.1% over the past year.

Return vs Market: BNR exceeded the US Market which returned 23.3% over the past year.

Price Volatility

Is BNR's price volatile compared to industry and market?
BNR volatility
BNR Average Weekly Movement15.0%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: BNR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BNR's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014667Yusheng Hanwww.brbiotech.com

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Burning Rock Biotech Limited Fundamentals Summary

How do Burning Rock Biotech's earnings and revenue compare to its market cap?
BNR fundamental statistics
Market capUS$176.12m
Earnings (TTM)-US$8.14m
Revenue (TTM)US$79.33m
2.2x
P/S Ratio
-21.6x
P/E Ratio

Is BNR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BNR income statement (TTM)
RevenueCN¥539.57m
Cost of RevenueCN¥136.65m
Gross ProfitCN¥402.91m
Other ExpensesCN¥458.26m
Earnings-CN¥55.35m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-5.25
Gross Margin74.67%
Net Profit Margin-10.26%
Debt/Equity Ratio0.4%

How did BNR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 12:06
End of Day Share Price 2026/05/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Burning Rock Biotech Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
null nullChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited